Phase 2 Ovarian Cancer Trial, Recruiting NCT02647827 Sponsor: Karolinska Institutet Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 2 Ovarian Cancer Trial, Recruiting

NCT02647827
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

(For women with PCOS):

  • You are between 18 and 40 years old
  • Your Body Mass Index (BMI) is between 25 and 40 (this is a measure of body weight relative to height)
  • You have been diagnosed with PCOS based on having at least two of the following: unusual hair growth or acne; irregular or absent periods (periods more than 35 days apart, fewer than 8 per year, or fewer than 3 per year); or cysts on the ovaries seen on an internal ultrasound scan
  • You are willing to sign a consent form agreeing to take part

(For comparison/control participants — women without PCOS):

  • You have a BMI between 25 and 40, regular periods roughly every 28 days, and no signs of excess hair growth or other PCOS symptoms

Who may not be able to join:

  • You are over 40 years old
  • You have certain other hormonal or gland-related conditions, such as a specific type of adrenal gland disorder, a hormone-producing tumour, or a suspected condition called Cushing's syndrome (confirm with trial site)
  • You have known kidney disease, liver problems, an autoimmune condition, or cancer
  • You have any ongoing condition that could suddenly affect your kidneys or reduce oxygen supply to your body's tissues (confirm with trial site)
  • You have Type 1 diabetes
  • You have taken certain medications in the last 12 weeks, including steroids (cortisone), antidepressants, other diabetes medicines (such as insulin), hormonal contraceptives, or hormone-based fertility treatments — or have had a long-acting contraceptive injection (such as Depo-Provera) in the last 6 months
  • You have a known allergy or sensitivity to metformin or any of its ingredients
  • Your blood pressure is higher than 160/100 mmHg
  • You are pregnant or have been breastfeeding in the last 6 months
  • You have had acupuncture in the last 2 months
  • You smoke daily or drink alcohol daily
  • There is a language barrier or another difficulty that would make it hard for you to fully understand the information provided about the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Elisabet Stener-Victorin, PhD, Karolinska Institutet

Phone: +46705643655

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 December 2015
Est. completion
1 June 2025

Where this trial is recruiting

🇨🇳 China 🇸🇪 Sweden

Primary endpoints

Changes from baseline to after 4 months in HOMA-IR [fasting insulin (μU/mL) × fasting glucose (mmol/L)] / 22.5); Changes from baseline to after 4 months of treatment in HbA1c; Changes from baseline to after 4 months of treatment in insulin response to glucose during the oral glucose tolerance test (OGTT)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov